Braeburn Appoints Joshua M. Cohen, MD, MPH, FAHS as Chief Medical Officer

Braeburn Appoints Joshua M. Cohen, MD, MPH, FAHS as Chief Medical Officer


Plymouth Meeting, Pa.—September 24, 2021—Braeburn announces that Joshua M. Cohen, MD, MPH, FAHS has joined the company as Chief Medical Officer. Dr. Cohen will play a critical role within Braeburn’s leadership team overseeing the medical affairs and research and development functions as the Company continues to grow.

Dr. Cohen brings extensive experience in pharmaceutical and clinical leadership as well as a strong commitment to advancing public health, policy, and research.  Prior to Braeburn, Josh served as the Global Medical Therapeutic Area Lead for Migraine & Headache at Teva where he provided dynamic leadership for global launches, leading a matrix team of medical directors, scientific communications, health economics and outcomes research, and other global and regional functions.

“The addition of Josh to Braeburn adds significant medical, clinical and public health knowledge to our experienced and dedicated Executive Leadership Team,” said Mike Derkacz, President and CEO of Braeburn. “Josh’s expertise along with his past product launch experience will provide a sound medical foundation as we work to develop and obtain approval for another treatment option for healthcare providers to treat their patients with opioid use disorder.”

Dr. Cohen completed undergraduate training at Harvard University, medical school at the New York University School of Medicine, and neurology residency at Columbia University’s Neurological Institute. At the Columbia Mailman School of Public Health, he received his Master of Public Health, and he completed headache fellowship at The Headache Institute. Additionally, he was chosen as a Super Doctors® 2013 and 2014 New York Rising Stars™ and was selected as a Castle Connolly America’s Top Doctors™ in 2015.

About Braeburn

Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder. Our mission is to advance next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers and society. For more information about Braeburn, please visit

For additional information, please contact:

Colleen Saltmer:

Define the future at Braeburn...together.

Join Our Team